The primary objective of this study is to determine safety and tolerability of Karonudib for
the treatment of hematological malignancies.
Secondary objectives are to determine a recommended RP2D and schedule for further development
of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of
treatment efficacy. Overall survival will also be recorded.